Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot
NA Ullman, PR Burchard, RF Dunne… - Journal of Clinical …, 2022 - ascopubs.org
The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …
[HTML][HTML] Challenges and opportunities for pancreatic cancer immunotherapy
AS Bear, RH Vonderheide, MH O'Hara - Cancer cell, 2020 - cell.com
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE …
LJ Padrón, DM Maurer, MH O'Hara, EM O'Reilly… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer
NG Steele, ES Carpenter, SB Kemp, VR Sirihorachai… - Nature Cancer, 2020 - nature.com
Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor
microenvironment that renders it largely refractory to immunotherapy. We implemented a …
microenvironment that renders it largely refractory to immunotherapy. We implemented a …
Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and
poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …
poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …
Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma
J Peng, BF Sun, CY Chen, JY Zhou, YS Chen, H Chen… - Cell research, 2019 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer
featured with high intra-tumoral heterogeneity and poor prognosis. To comprehensively …
featured with high intra-tumoral heterogeneity and poor prognosis. To comprehensively …
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
M Orth, P Metzger, S Gerum, J Mayerle, G Schneider… - Radiation …, 2019 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
prognosis and rising incidence. Late detection and a particularly aggressive biology are the …
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is considered non-immunogenic, with trials
showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we …
showing its recalcitrance to PD1 and CTLA4 immune checkpoint therapies (ICTs). Here, we …
Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy
The biological and functional heterogeneity between tumors—both across and within cancer
types—poses a challenge for immunotherapy. To understand the factors underlying tumor …
types—poses a challenge for immunotherapy. To understand the factors underlying tumor …
[HTML][HTML] The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
WA Freed-Pastor, LJ Lambert, ZA Ely, NB Pattada… - Cancer cell, 2021 - cell.com
The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …